S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:EFTR

eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis

$14.39
+0.94 (+6.99%)
(As of 03/28/2024 ET)
Today's Range
$13.25
$14.72
50-Day Range
$9.08
$16.95
52-Week Range
$8.44
$37.00
Volume
349,809 shs
Average Volume
211,232 shs
Market Capitalization
$37.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00

eFFECTOR Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
66.8% Upside
$24.00 Price Target
Short Interest
Bearish
15.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.80mentions of eFFECTOR Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.62) to ($2.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.18 out of 5 stars

Medical Sector

585th out of 939 stocks

Pharmaceutical Preparations Industry

278th out of 444 stocks

EFTR stock logo

About eFFECTOR Therapeutics Stock (NASDAQ:EFTR)

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

EFTR Stock Price History

EFTR Stock News Headlines

Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
eFFECTOR Therapeutics (NASDAQ: EFTR)
See More Headlines
Receive EFTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EFTR
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.00
High Stock Price Target
$24.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+66.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-22,670,000.00
Pretax Margin
-5,332.49%

Debt

Sales & Book Value

Annual Sales
$3.55 million
Book Value
$2.34 per share

Miscellaneous

Free Float
2,368,000
Market Cap
$37.13 million
Optionable
Optionable
Beta
0.52
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Stephen T. Worland Ph.D. (Age 66)
    CEO, President & Director
    Comp: $855.25k
  • Mr. Michael Byrnes M.B.A. (Age 47)
    Chief Financial Officer
    Comp: $623.69k
  • Dr. Douglas Warner M.D. (Age 52)
    Chief Medical Officer
    Comp: $304.4k
  • Dr. Davide Ruggero Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Kevan M. Shokat Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board

EFTR Stock Analysis - Frequently Asked Questions

Should I buy or sell eFFECTOR Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for eFFECTOR Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EFTR shares.
View EFTR analyst ratings
or view top-rated stocks.

What is eFFECTOR Therapeutics' stock price target for 2024?

2 equities research analysts have issued 12-month price objectives for eFFECTOR Therapeutics' shares. Their EFTR share price targets range from $24.00 to $24.00. On average, they anticipate the company's stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 66.8% from the stock's current price.
View analysts price targets for EFTR
or view top-rated stocks among Wall Street analysts.

How have EFTR shares performed in 2024?

eFFECTOR Therapeutics' stock was trading at $11.6850 at the beginning of 2024. Since then, EFTR stock has increased by 23.1% and is now trading at $14.39.
View the best growth stocks for 2024 here
.

Are investors shorting eFFECTOR Therapeutics?

eFFECTOR Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 318,100 shares, an increase of 43.1% from the February 29th total of 222,300 shares. Based on an average daily volume of 144,200 shares, the short-interest ratio is currently 2.2 days. Approximately 15.0% of the shares of the company are sold short.
View eFFECTOR Therapeutics' Short Interest
.

When is eFFECTOR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EFTR earnings forecast
.

How were eFFECTOR Therapeutics' earnings last quarter?

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) announced its quarterly earnings results on Monday, November, 8th. The company reported $10.50 EPS for the quarter, topping analysts' consensus estimates of ($6.50) by $17.00. The firm had revenue of $0.43 million for the quarter.

When did eFFECTOR Therapeutics' stock split?

Shares of eFFECTOR Therapeutics reverse split on Friday, January 12th 2024. The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are eFFECTOR Therapeutics' major shareholders?

eFFECTOR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (22.26%), Vanguard Group Inc. (22.22%) and Northern Trust Corp (6.23%). Insiders that own company stock include Brian M Jr Gallagher, Christopher B Ehrlich, Jonathan D Root, Michael Byrnes, Presidio Management Group X Ll, Sr One Capital Management, Llc and Stephen T Worland.
View institutional ownership trends
.

How do I buy shares of eFFECTOR Therapeutics?

Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EFTR) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners